Amarin opened lower at $11.64, compared with its previous close of $11.71. In the last trading session, the stock traded between $11.40 and $11.71. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Amarin is now worth
$ 14.19
Resulting in a loss of
$ 85.81 (85.81%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
0%
Hold
0%
Sell
100%
Markets Today
Today's Change
$-0.04 (-0.36%)
Day High
$11.71
Day Low
$11.40
Day Open
$11.64
Prev Close
$11.71
Volume
56,355
1W Return
-4.71%
1M Return
1.33%
3M Return
-16.67%
6M Return
-22.32%
1Y Return
-27.48%
Fundamentals
Market Cap ($ Mn)
246
PE Ratio
-
PB Ratio
0.66
PEG Ratio
-
ROE
-8.28%
ROCE
-9.62%
EPS (TTM)
$0.00
Investment Returns
1 Week
-4.71%
1 Month
1.33%
3 Months
-16.67%
6 Months
-22.32%
9 Months
-22.78%
Financials
Quarterly
All values in $ Mn
72.7
Jun 25
49.7
Sep 25
49.2
Dec 25
45.1
Mar 26
42.2
Jun 26
39.5
Sep 26
Updates
9Nov
Amarin presents new clinical data on Lp(a) predictors of MACE
Amarin Corporation plc presented new clinical data on Lp(a) and apoB lipoproteins as predictors of MACE at AHA Scientific Sessions 2026. Research examines EPA effects on Lp(a) oxidation and inflammatory pathways. Data builds on REDUCE-IT analysis showing IPE reduced MACE across Lp(a) concentrations. Findings address residual cardiovascular risk following Lp(a)HORIZON trial failure to meet primary endpoint.
3 days ago
31Aug
Amarin REDUCE-IT data shows 30% CV risk drop with adherence
Highly adherent REDUCE-IT participants saw ~30% relative risk reduction in major adverse cardiovascular events. Secondary prevention patients showed persistent "legacy" benefits with hazard ratio of 0.73 even after stopping treatment. New mechanistic data shows EPA limits rapid oxidation of Lp(a) and reduces tissue factor levels. 2026 ESC/ERA guidelines recognize icosapent ethyl's benefit in patients with chronic kidney disease. Women discontinued study participation earlier than men, though this was consistent across treatment and placebo arms.
2mo ago
22Aug
JP Morgan reinstates Underweight on Amarin Corp with $13 target
JP Morgan reinstates Underweight rating on Amarin Corp. Analyst Jessica Fye sets a $13 price target for the stock. The move signals a cautious valuation outlook from the bank.
2mo ago
1Jul
Amarin highlights VASCEPA value amid new sHTG therapies
Amarin Corporation plc reaffirmed the role of VASCEPA (icosapent ethyl) as a cost-effective, guideline-recommended therapy following FDA approval of injectable APOC3 therapies for severe hypertriglyceridemia. CEO Aaron Berg emphasized VASCEPA's proven efficacy and lower annual cost of $4,200 compared to $40,000 for new injectables.
